Alterações na leptina e adiponectina em pacientes com obesidade e suas implicações clínicas
DOI:
https://doi.org/10.5281/zenodo.14888355Palavras-chave:
Adiponectina, Leptina, Obesidade, TerapêuticaResumo
A obesidade é uma condição metabólica complexa, associada a alterações na secreção de adipocinas, incluindo leptina e adiponectina, que desempenham papéis fundamentais na regulação da homeostase energética e da inflamação. Este estudo teve como objetivo analisar as modificações nos níveis dessas adipocinas em pacientes com obesidade e suas implicações clínicas. Para isso, foi conduzida uma revisão integrativa da literatura em bases de dados científicas, selecionando artigos publicados entre 2020 e 2025. Os resultados indicaram que a obesidade está associada a um aumento da leptina circulante e à redução da adiponectina, contribuindo para resistência à leptina, inflamação crônica e maior risco de doenças metabólicas, como diabetes mellitus tipo 2 e dislipidemias. Além disso, a razão leptina/adiponectina demonstrou ser um biomarcador promissor na avaliação do risco cardiometabólico. Intervenções baseadas em modificações no estilo de vida, incluindo dietas balanceadas e atividade física, mostraram-se eficazes na normalização desses hormônios. Estratégias farmacológicas, como o uso de sensibilizadores de insulina e inibidores de mediadores inflamatórios, também foram exploradas como potenciais abordagens terapêuticas. Conclui-se que a compreensão do papel das adipocinas na obesidade é essencial para o desenvolvimento de estratégias terapêuticas mais eficazes, contribuindo para a redução das complicações metabólicas associadas a essa condição.
Referências
BLÜHER, M. Obesity: global epidemiology and pathogenesis. Nature Reviews Endocrinology, [s. l.], v. 15, p. 288-298, 2019. DOI: 10.1038/s41574-019-0176-8.
CASTELA, I. et al. Decreased adiponectin/leptin ratio relates to insulin resistance in adults with obesity. American Journal of Physiology, Endocrinology and Metabolism, [s. l.], v. 324, p. E115-E119, 2023. DOI: 10.1152/ajpendo.00273.2022.
COJOCARU, K. A. et al. Mitochondrial Dysfunction, Oxidative Stress, and Therapeutic Strategies in Diabetes, Obesity, and Cardiovascular Disease. Antioxidants, [s. l.], v. 12, n. 3, p. 658, 2023. DOI: 10.3390/antiox12030658.
CRUCIANI, S. et al. Management of Obesity and Obesity-Related Disorders: From Stem Cells and Epigenetics to Its Treatment. International Journal of Molecular Sciences, [s. l.], v. 24, n. 3, p. 2310, 2023. DOI: 10.3390/ijms24032310.
DANTAS, H. L. L. et al. Como elaborar uma revisão integrativa: sistematização do método científico. Revista Científica de Enfermagem, São Paulo, v. 12, n. 37, p. 334-345, 2021. DOI: 10.24276/rrecien2022.12.37.334-345.
DESSIE, G. et al. Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, [s. l.], v. 14, p. 3307-3322, 2021. DOI: 10.2147/DMSO.S321311.
DLUDLA, P. V. et al. Adipokines as a therapeutic target by metformin to improve metabolic function: A systematic review of randomized controlled trials. Pharmacological Research, [s. l.], v. 163, p. 105219, 2021. DOI: 10.1016/j.phrs.2020.105219.
FRIEDMAN, J. M. Leptin and the endocrine control of energy balance. Nature Metabolism, [s. l.], v. 1, p. 754-764, 2019. DOI: 10.1038/s42255-019-0095-y.
FRÜHBECK, G. et al. Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesity-associated cardiometabolic risk. Adipocyte, [s. l.], v. 7, n. 1, p. 57 - 62, 2018. DOI: 10.1080/21623945.2017.1402151.
JIANG, Z. et al. The Adiponectin-SIRT1-AMPK Pathway in Alcoholic Fatty Liver Disease in the Rat. Alcoholism: Clinical and Experimental Research, [s. l.], v. 39, n. 3, p. 424-433, 2015. DOI: 10.1111/acer.12641.
KAZEMINASAB, F. et al. Effects of plant-based diets combined with exercise training on leptin and adiponectin levels in adults with or without chronic diseases: a systematic review and meta-analysis of clinical studies. Frontiers in Nutrition, [s. l.], v. 11, n. 1465378, 2024. DOI: 10.3389/fnut.2024.1465378.
KORAC, A. et al. Adipokine signatures of subcutaneous and visceral abdominal fat in normal-weight and obese women with different metabolic profiles. Archives of Medical Science, [s. l.], v. 17, n. 2, p. 323-336, 2021. DOI: 10.5114/aoms/92118.
KOTAL, S. et al. A Review on Role of Different Adipokines in Gestational Diabetes. Journal of Advanced Zoology, [s. l.], v. 44, n. S6, p. 2109-2113, 2023. DOI: 10.17762/jaz.v44iS6.2794.
KWON, O.; KIM, K. W.; KIM, M. S. Leptin signalling pathways in hypothalamic neurons. Cellular and Molecular Life Sciences, [s. l.], v. 73, p. 1457-1477, 2016. DOI: 10.1007/s00018-016-2133-1.
LA PAZ, S. M. et al. Nutritional modulation of leptin expression and leptin action in obesity and obesity-associated complications. The Journal of Nutritional Biochemistry, [s. l.], v. 89, p. 108561, 2021. DOI: 10.1016/j.jnutbio.2020.108561.
LEDERER, A. K. et al. Plasma Leptin and Adiponectin after a 4-Week Vegan Diet: A Randomized-Controlled Pilot Trial in Healthy Participants. International Journal of Environmental Research and Public Health, [s. l.], v. 19, n. 11370, p. 1-14, 2022. DOI: 10.3390/ijerph191811370.
LIU, W. et al. Serum leptin, resistin, and adiponectin levels in obese and non-obese patients with newly diagnosed type 2 diabetes mellitus: A population-based study. Medicine, Baltimore, v. 99, n. 6, p. e19052, 2020. DOI: 10.1097/MD.0000000000019052.
LONGO, M. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International Journal of Molecular Sciences, [s. l.], v. 20, n. 9, p. 2358, 2019. DOI: 10.3390/ijms20092358.
MAYERHOFER, E. et al. A Multidisciplinary Intervention in Childhood Obesity Acutely Improves Insulin Resistance and Inflammatory Markers Independent From Body Composition. Frontiers in Pediatrics, [s. l.], v. 8, p. 52, 2020. DOI: 10.3389/fped.2020.00052.
MILLAR, S. R.; PERRY, I. J.; PHILLIPS, C. M. Anthropometric measures, predicted visceral adipose tissue and biomarkers of chronic inflammation. European Journal of Clinical Investigation, [s. l.], v. 54, n. 2, p. e14104, 2023. DOI: 10.1111/eci.14104.
MILLER, E. S. et al. Chronic stress induces persistent low-grade inflammation. American Journal of Surgery, [s. l.], v. 218, n. 4, p. 677-683, 2019. DOI: 10.1016/j.amjsurg.2019.07.006.
MIR, M. M. et al. Differential Association of Selected Adipocytokines, Adiponectin, Leptin, Resistin, Visfatin and Chemerin, with the Pathogenesis and Progression of Type 2 Diabetes Mellitus (T2DM) in the Asir Region of Saudi Arabia: A Case Control Study. Journal of Personalized Medicine, [s. l.], v. 12, n. 735, p. 1-16, 2022. DOI: 10.3390/jpm12050735.
NAMBI, G. et al. Clinical (BMI and MRI) and Biochemical (Adiponectin, Leptin, TNF-α, and IL-6) Effects of High-Intensity Aerobic Training with High-Protein Diet in Children with Obesity Following COVID-19 Infection. International Journal of Molecular Sciences, [s. l.], v. 19, n. 7194, p. 1-12, 2022. DOI: 10.3390/ijerph19127194.
OBRADOVIC, M. et al. Leptin and Obesity: Role and Clinical Implication. Frontiers in Endocrinology, [s. l.], v. 12, n. 585887, 2021. DOI: 10.3389/fendo.2021.585887.
RAFEY, M. F. et al. Changes in the Leptin to Adiponectin Ratio Are Proportional to Weight Loss After Meal Replacement in Adults With Severe Obesity. Frontiers in Nutrition, [s. l.], v. 9, n. 845574, 2022. DOI: 10.3389/fnut.2022.845574.
RAJESH, Y.; SARKAR, D. Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer. International Journal of Molecular Sciences, [s. l.], v. 22, n. 2163, p. 1-28, 2021. DOI: 10.3390/ijms22042163.
RECINELLA, L. et al. Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases. Frontiers in Physiology, [s. l.], v. 11, 2020. DOI: 10.3389/fphys.2020.578966.
REJEKI, P. S. et al. The Positive Effect of Four-Week Combined Aerobic-Resistance Training on Body Composition and Adipokine Levels in Obese Females. Sports, Basel, v. 11, n. 4, p. 90, 2023. DOI: 10.3390/sports11040090.
REN, Y. et al. Adipokines, Hepatokines and Myokines: Focus on Their Role and Molecular Mechanisms in Adipose Tissue Inflammation. Frontiers in Endocrinology, [s. l.], v. 13, n. 873699, p. 1-26, 2022. DOI: 10.3389/fendo.2022.873699.
RIZZO, M., FASANO, R., & PAOLISSO, G. Adiponectin and Cognitive Decline. International Journal of Molecular Sciences, [s. l.], v. 21, n. 6, p. 2010, 2020. DOI: 10.3390/ijms21062010.
SAHIN-EFE, A. et al. Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: A cross sectional and a prospective case-control study nested in the Normative Aging Study. Metabolism, [s. l.], v. 79, p. 24-32, 2018. DOI: 10.1016/j.metabol.2017.10.011.
SENKUS, K. E. et al. Changes in adiponectin:leptin ratio among older adults with obesity following a 12-month exercise and diet intervention. Nutrition & Diabetes, [s. l.], v. 12, n. 30, p. 1-7, 2022. DOI:10.1038/s41387-022-00207-1.
SHAMS, H. A.; AZIZ, H. M.; AL-KURAISHY, H. M. The potential effects of metformin and/or sitagliptin on leptin/adiponectin ratio in diabetic obese patients: a new therapeutic effect. The Journal of the Pakistan Medical Association, [s. l.], v. 74, n. 10, Suppl. 8, p. S241-S245, 2024. DOI: 10.47391/JPMA-BAGH-16-54.
STEIN, R.; FERRARI, F.; SCOLARI, F. Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights. Current Cardiology Reports, [s. l.], v. 21, n. 68, p. 1-12, 2019. DOI: 10.1007/s11886-019-1161-5.
STRAUB, L. G.; SCHERER, P. E. Metabolic Messengers: adiponectin. Nature Metabolism, [s. l.], v. 1, p. 334-339, 2019. DOI: 10.1038/s42255-019-0041-z.
WU, P. et al. Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2 Diabetes. Hormone and Metabolic Research, [s. l.], v. 51, n. 8, p. 487-494, 2019. DOI: 10.1055/a-0958-2441.
WUEEST, S. et al. IL-6 Receptor Blockade Increases Circulating Adiponectin Levels in People with Obesity: An Explanatory Analysis. Metabolites, [s. l.], v. 11, n. 79, p. 1-7, 2021. DOI: 10.3390/metabo11020079.
WÜRFEL, M. et al. Adipokines as Clinically Relevant Therapeutic Targets in Obesity. Biomedicines, [s. l.], v. 11, n. 1427, p. 1-26, 2023. DOI: 10.3390/biomedicines11051427.
ZHAO, Q. Y. et al. Assessment of mitochondrial function in metabolic dysfunction-associated fatty liver disease using obese mouse models. Zoological Research, [s. l.], v. 41, n. 5, p. 539-551, 2020. DOI: 10.24272/j.issn.2095-8137.2020.051.
ZHAO, S.; KUSMINSKI, C. M.; SCHERER, P. E. Adiponectin, Leptin and Cardiovascular Disorders. Circulation Research, [s. l.], v. 128, n. 1, p. 136-149, 2021. DOI: 10.1161/CIRCRESAHA.120.314458.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2025 Journal of Social Issues and Health Sciences (JSIHS)

Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.